You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Gallium 68 Tilmanocept for PET Imaging of Atherosclerosis Plaques

    SBC: Navidea Biopharmaceuticals, Inc.            Topic: NHLBI

    Myocardial infarctionsMIor heart attacksischemic strokesISand peripheral artery diseasePADtogether considered cardiovascular diseaseCVDare all commonly caused by the same underlying pathologyatherosclerosisMIs and ISs are the leading causes of death and disability worldwideAtherosclerosis is a progressive pathology that develops asymptomatically over the course of many years as inflammatory plaque ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Targeting neurotoxic alpha-synuclein aggregates for Parkinson's disease therapy.

    SBC: Vova Ida, LLC            Topic: 999

    SUMMARYParkinsonandapos s diseasePDis the second most prevalent neurodegenerative disorder after Alzheimerandapos s diseaseADaffecting more thanmillion people in the United StatesBecause age is the major risk factorthe prevalence of both diseases is steadily increasing as our population agesPD belongs to the group of protein misfolding neurodegenerative diseases that are due to the misfolding and ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. rAAV5-hCNGB3 Gene Therapy for Achromatopsia: Safety and Efficacy in a Dog Model

    SBC: APPLIED GENETIC TECHNOLOGIES CORPORATION            Topic: N

    DESCRIPTION provided by applicant Complete achromatopsia is an autosomal recessive inherited congenital disorder of retinal cone photoreceptors Patients with complete achromatopsia experience extreme light sensitivity and daytime blindness and best visual acuity under non bright light conditions is usually or worse and generally stable over time In addition to poor acuity hypersensit ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  4. Acute-infarct selective cardiac MRI contrast agent

    SBC: ELGAVISH PARAMAGNETICS, INC.            Topic: NHLBI

    DESCRIPTION provided by applicant The overall goal of this project is to demonstrate the ability of our acute myocardial infarct selective paramagnetic contrast agent Gadolinium ABE DTTA to differentiate between acute and chronic infarcts in a reliable manner using contrast enhanced magnetic resonance imaging ceMRI In our Phase I data we have shown that Gd ABE DTTA exclusively highlight ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  5. A Device to Quantify Sweat of Single Sweat Glands to Diagnose Neuropathy

    SBC: Neuro Devices, Inc.            Topic: 107

    DESCRIPTION provided by applicant We devised a new generation highly sensitivity method to diagnosis peripheral neuropathy early when the probability for reversal is greatest Cancer chemotherapy and diabetes are the most common causes of neuropathy in the USA Both cause decreased sweating abnormal circulation peripheral numbness pain and weakness If diagnosed early both are potentially ...

    STTR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  6. Developing a Small Peptide to Control Autoimmune Inflammation In Type 1 Diabetes

    SBC: Op-T-Mune, Inc            Topic: NIAID

    Type 1 Diabetes (T1D) affects an ever growing population. While this disease typically has been associated with juveniles, the disease in adult populations is rapidly increasing. The defining clinical component is insulin loss, which occurs because of sustained inflammation in the islets. At present there is no means to prevent or reverse insulin loss. A major inflammatory pathway in T1D that cont ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Targeting bacteria, the innate response of the middle ear to infection, and host-pathogen interactions, using topical and transtympanic applications for the treatment of otitis media.

    SBC: EARNANO LLC            Topic: NICHD

    Otitis media is a world wide disease primarily affecting the pediatric population under the age ofyearsIt is the most common reason for pediatric care visits and antibiotic therapyOver prescription and poorcompliance have led to a reduced susceptibility of bacteria to antibiotics andconsequentiallyto recurrent and chronic ear diseasesClearlythere is a compelling need to investigate alternative the ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. The Point Digit: A ratcheting prosthetic finger using advanced rapid manufacturing technology

    SBC: POINT DESIGNS, LLC            Topic: NICHD

    The Point DigitA Ratcheting Prosthetic Finger UsingAdvanced Rapid Manufacturing Technology Project SummaryAbstract The goal of the proposed project is to develop and commercialize a purely mechanicalratcheting prosthetic fingerthe Point Digitwhichhas an industry leading strength to weight ratiocan be operated unilaterallyone handedoffers anatomical rotation and flexion around the patient s metacar ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. A Portable Device for Accurate Mouse Tail Vein Injection

    SBC: Technology Commercialization Partners LLC            Topic: OD

    PROJECT SUMMARYABSTRACT To datethe standard method to access a mouse tail vein is manual injectionbut its yield rate is poor in generalThis leads to multiple needle insertions associated with tissue damage and painBesidesfailure in tail vein injection leads to data lossand thereby more animals will be required to compensate itFinallythe dose variation induced by unreliable injection increases erro ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Evolution of an Adaptable Prosthetic Foot Design for Normalization of Biomechanics During Community Participation

    SBC: OHIO WILLOW WOOD COMPANY, THE            Topic: NICHD

    Evolution of an Adaptable Prosthetic Foot Design for Normalization ofBiomechanics During Community Participation Summary/AbstractThe vision of this project is to improve the functional physical mobility of people with lower extremity amputations especially on uneven ground, side-slopes or when foot placement varies from side-to-side. People with amputations will be enabled to confidently participa ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government